Gsk (GSK) Intangibles (2009 - 2026)
Gsk (GSK) posted quarterly Intangibles of $22.5 billion for Q2 2026, up 9.9% year-over-year from $20.5 billion in Q2 2025, and down 7.81% quarter-over-quarter from $24.5 billion in Q1 2026.
Gsk (GSK) Intangibles (2009 - 2026) Analysis & Trends
Gsk's Intangibles history runs 18 years deep, the most recent figure standing at $22.5 billion for Q2 2026.
- In Q2 2026, Intangibles rose 9.9% year-over-year to $22.5 billion; the TTM figure through Jun 2026 stood at $22.5 billion (up 9.9% YoY), while the FY2025 annual figure was $22.1 billion, up 11.34% from the prior year.
- Intangibles for Q2 2026 stood at $22.5 billion, down from $24.5 billion in the prior quarter.
- The five-year high for Intangibles was $26.0 billion in Q1 2022, with the low at $14.3 billion in Q2 2022.
- The 5-year median for Intangibles is $19.7 billion (2024), against an average of $20.1 billion.
- The sharpest annual moves came in 2022 and 2023: Intangibles sank 65.07% in 2022, then soared 35.72% in 2023.
- Gsk's Intangibles stood at $16.8 billion in 2022, then rose by 9.14% to $18.3 billion in 2023, then grew by 8.64% to $19.9 billion in 2024, then grew by 11.87% to $22.3 billion in 2025, then increased by 1.19% to $22.5 billion in 2026.
- Business Quant data shows GSK's Intangibles at $22.5 billion in Q2 2026, $24.5 billion in Q1 2026, and $22.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 48.23 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 49.14 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 24.98 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 42.07 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 37.72 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 20.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 14.03 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 47.05 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 22.54 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 30.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.54 Bn |
| Mar 31, 2026 | 24.45 Bn |
| Dec 31, 2025 | 22.28 Bn |
| Sep 30, 2025 | 22.76 Bn |
| Jun 30, 2025 | 20.51 Bn |
| Mar 31, 2025 | 20.48 Bn |
| Dec 31, 2024 | 19.91 Bn |
| Sep 30, 2024 | 19.50 Bn |
| Jun 30, 2024 | 19.53 Bn |
| Mar 31, 2024 | 19.87 Bn |
| Dec 31, 2023 | 18.33 Bn |
| Sep 30, 2023 | 19.37 Bn |
| Jun 30, 2023 | 19.43 Bn |
| Mar 31, 2023 | 17.21 Bn |
| Dec 31, 2022 | 16.79 Bn |
| Sep 30, 2022 | 18.37 Bn |
| Jun 30, 2022 | 14.32 Bn |
| Mar 31, 2022 | 26.04 Bn |
| Dec 31, 2021 | 40.55 Bn |
| Sep 30, 2021 | 41.69 Bn |